Value through Innovation27 July 2016

Clinical Study Results

  • Afatinib + Nintedanib - Neoplasms
    Clinical Study Number 1239.1
    Study Indication Neoplasms
    Product Afatinib + Nintedanib
    Generic Name Afatinib + Nintedanib
    Lab Code
    Clinical Phase I
    Study Title

    A combination Phase I open-label dose escalation study of concomitant administration of BIBW 2992 with BIBF 1120 in patients with advanced solid tumors

    Study Document Trial synopsis 1239.1_DR english
  • Afatinib + Nintedanib - Colorectal Neoplasms
    Clinical Study Number 1239.2
    Study Indication Colorectal Neoplasms
    Product Afatinib + Nintedanib
    Generic Name Afatinib + Nintedanib
    Lab Code
    Clinical Phase II
    Study Title

    A phase II trial of weekly alternating sequential administration of BIBF 1120 and BIBW 2992 in patients with advanced colorectal cancer

    Study Document Trial synopsis 1239.2_DR english
  • Afatinib + Nintedanib - Prostatic Neoplasms
    Clinical Study Number 1239.3
    Study Indication Prostatic Neoplasms
    Product Afatinib + Nintedanib
    Generic Name Afatinib + Nintedanib
    Lab Code
    Clinical Phase II
    Study Title

    A multi-centre 3-arm randomised phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer

    Study Document Trial synopsis 1239.3_DS_DR english
  • Afatinib + Nintedanib - Neoplasms
    Clinical Study Number 1239.14
    Study Indication Neoplasms
    Product Afatinib + Nintedanib
    Generic Name Afatinib + Nintedanib
    Lab Code
    Clinical Phase I
    Study Title

    Phase I Dose escalation study of concomitant BIBF 1120 and BIBW 2992 in patients with advanced solid tumours.

    Study Document Trial synopsis 1239.14_PE english Trial synopsis 1239.14 english
  • Afatinib + Nintedanib - Colorectal Neoplasms
    Clinical Study Number 1239.6
    Study Indication Colorectal Neoplasms
    Product Afatinib + Nintedanib
    Generic Name Afatinib + Nintedanib
    Lab Code
    Clinical Phase II
    Study Title

    A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 50 mg once daily (BB) versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer

    Study Document Trial statement 1239.6 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.